GSK gives reticent HGS investors more time

Pharmaceutical giant GlaxoSmithKline has given investors in takeover target Human Genome Sciences (HGS) more time to tender their shares.

Pharmaceutical giant GlaxoSmithKline has given investors in takeover target Human Genome Sciences (HGS) more time to tender their shares.

GSK said that when its original offer expired at midnight on Friday it had collected 79% of the HGS shares.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.